TY - JOUR
T1 - Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial
AU - Lublin, Henrik
AU - Haug, Hans-Joachim
AU - Koponen, Hannu
AU - Sigmundsson, Thordur
AU - Kolb, Stefan A
AU - Lublin, Henrik
AU - Haug, Hans-Joachim
AU - Koponen, Hannu
AU - Sigmundsson, Thordur
AU - Kolb, Stefan A
N1 - Keywords: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholesterol; Chronic Disease; Dibenzothiazepines; Drug Tolerance; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Risperidone; Schizophrenia; Thiazoles; Triglycerides; Young Adult
PY - 2009
Y1 - 2009
N2 - The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator. A total of 293 patients were randomized to 12 weeks treatment with either ziprasidone 80-160 mg/day (n=147) or with one of the comparator drugs (n=146). In the latter group the investigator could choose between olanzapine 10-20 mg/day (n=24), risperidone 4-8 mg/day (n=22) or quetiapine 300-750 mg/day (n=97). The study comprised four visits including a baseline examination prior to randomization and further examinations at the end of weeks 1, 4 and 12. Ziprasidone was non-inferior (defined as a difference of 7 units or less on the PANSS scale to the disadvantage of ziprasidone) to the composite group (olanzapine, risperidone or quetiapine) on the total PANSS score as well as on all subscores (P<0.0001); there were no significant between-group differences in the CGI-S and I and UKU scores. Ziprasidone-treated patients lost an average of 2.1 kg in the 12 weeks of the study, the mean weight for risperidone and quetiapine remained unchanged, and patients receiving olanzapine gained 3.1 kg on average.
AB - The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator. A total of 293 patients were randomized to 12 weeks treatment with either ziprasidone 80-160 mg/day (n=147) or with one of the comparator drugs (n=146). In the latter group the investigator could choose between olanzapine 10-20 mg/day (n=24), risperidone 4-8 mg/day (n=22) or quetiapine 300-750 mg/day (n=97). The study comprised four visits including a baseline examination prior to randomization and further examinations at the end of weeks 1, 4 and 12. Ziprasidone was non-inferior (defined as a difference of 7 units or less on the PANSS scale to the disadvantage of ziprasidone) to the composite group (olanzapine, risperidone or quetiapine) on the total PANSS score as well as on all subscores (P<0.0001); there were no significant between-group differences in the CGI-S and I and UKU scores. Ziprasidone-treated patients lost an average of 2.1 kg in the 12 weeks of the study, the mean weight for risperidone and quetiapine remained unchanged, and patients receiving olanzapine gained 3.1 kg on average.
U2 - 10.1080/15622970802269589
DO - 10.1080/15622970802269589
M3 - Journal article
C2 - 18803070
SN - 1562-2975
VL - 10
SP - 710
EP - 718
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 4 Pt 3
ER -